Mitsubishi Tanabe Pharma Corporation

Shinsuke Ooike

Kunio Sugahara

Shinji Miyoshi

Hidemasa Hikawa

Kazunori Iwata

Masayuki Hayashi

Hiroshi Ikegami

Yasuhiro Fujino

Masahiko Morioka

Makoto Sakiyama

Daisuke Abe

Hideo Tomozane

The invention provides a method of inhibiting binding between acetylated histone and a bromodomain-containing protein in a mammal, as well as a method of shrinking or killing of cancer cells expressing a bromodomain-containing protein or inhibiting the growth of cancer cells expressing a bromodomain-containing protein in a mammal. The methods involve administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to the mammal.

Antitumor agent

The present invention relates to a novel antitumor agent containing a compound that inhibits binding between acetylated histone and a bromodomain-containing protein, preferably a thienotriazolodiazepine compound represented by the following formula (I) wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof or a hydrate or solvate as an active ingredient.

A therapeutic drug for cancer containing a substance selected from the group consisting of a novel cyanopyridine derivative, a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate as an active ingredient can be provided.

Cyanopyridine derivative and use thereof as medicine

Growing community of inventors

Osaka, Japan

Shinsuke Ooike